PL359238A1 - 16,17-karbocykliczne skondensowane związki steroidowe o selektywnej aktywności estrogennej - Google Patents

16,17-karbocykliczne skondensowane związki steroidowe o selektywnej aktywności estrogennej

Info

Publication number
PL359238A1
PL359238A1 PL01359238A PL35923801A PL359238A1 PL 359238 A1 PL359238 A1 PL 359238A1 PL 01359238 A PL01359238 A PL 01359238A PL 35923801 A PL35923801 A PL 35923801A PL 359238 A1 PL359238 A1 PL 359238A1
Authority
PL
Poland
Prior art keywords
alkenyl
alkyl
alkynyl
group
mdash
Prior art date
Application number
PL01359238A
Other languages
English (en)
Other versions
PL203732B1 (pl
Inventor
Hubert Jan Józef Loozen
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of PL359238A1 publication Critical patent/PL359238A1/pl
Publication of PL203732B1 publication Critical patent/PL203732B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL359238A 2000-06-06 2001-05-01 16,17-karbocykliczny skondensowany związek steroidowy, sposób selektywnej modyfikacji receptorów estrogenowych oraz zastosowanie związków steroidowych PL203732B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00201986 2000-06-06
PCT/EP2001/004868 WO2002000682A1 (en) 2000-06-06 2001-05-01 16, 17-carbocyclic condensed steroid compounds having selective estrogenic activity

Publications (2)

Publication Number Publication Date
PL359238A1 true PL359238A1 (pl) 2004-08-23
PL203732B1 PL203732B1 (pl) 2009-11-30

Family

ID=8171601

Family Applications (1)

Application Number Title Priority Date Filing Date
PL359238A PL203732B1 (pl) 2000-06-06 2001-05-01 16,17-karbocykliczny skondensowany związek steroidowy, sposób selektywnej modyfikacji receptorów estrogenowych oraz zastosowanie związków steroidowych

Country Status (27)

Country Link
US (3) US7868193B2 (pl)
EP (1) EP1294739B1 (pl)
JP (1) JP5095902B2 (pl)
KR (1) KR100769865B1 (pl)
CN (1) CN1235908C (pl)
AR (1) AR028080A1 (pl)
AT (1) ATE293124T1 (pl)
AU (2) AU2001258386B2 (pl)
BR (1) BR0111445A (pl)
CA (1) CA2410220C (pl)
CZ (1) CZ20024014A3 (pl)
DE (1) DE60110069T2 (pl)
DK (1) DK1294739T3 (pl)
ES (1) ES2240454T3 (pl)
HK (1) HK1052012A1 (pl)
HU (1) HUP0301190A3 (pl)
IL (1) IL152957A0 (pl)
MX (1) MXPA02012117A (pl)
NO (1) NO324247B1 (pl)
PE (1) PE20020214A1 (pl)
PL (1) PL203732B1 (pl)
PT (1) PT1294739E (pl)
RU (1) RU2255090C2 (pl)
SK (1) SK286852B6 (pl)
TW (1) TWI225068B (pl)
WO (1) WO2002000682A1 (pl)
ZA (1) ZA200209452B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367648B2 (en) 2009-06-10 2013-02-05 Msd Oss B.V. Substituted 16,17-annellated steroid compounds for use in womens healthcare
TW201109346A (en) * 2009-06-10 2011-03-16 Organon Nv Substituted 16,17-annellated steroid compounds for use in women's healthcare

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3194821A (en) * 1963-12-30 1965-07-13 Abbott Lab 17alpha-substituted 17beta-hydroxyestrenes
CA2200423C (en) 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
TW403736B (en) * 1997-02-21 2000-09-01 Akzo Nobel Nv Steroid compounds having contraceptive and anti-osteoporosis activity

Also Published As

Publication number Publication date
KR100769865B1 (ko) 2007-10-25
US20110224183A1 (en) 2011-09-15
NO20025793L (no) 2002-12-02
TWI225068B (en) 2004-12-11
CZ20024014A3 (cs) 2003-04-16
ATE293124T1 (de) 2005-04-15
SK286852B6 (sk) 2009-06-05
HUP0301190A2 (hu) 2003-08-28
PT1294739E (pt) 2005-06-30
BR0111445A (pt) 2003-06-03
US20100249083A1 (en) 2010-09-30
PE20020214A1 (es) 2002-03-13
HUP0301190A3 (en) 2010-03-29
JP5095902B2 (ja) 2012-12-12
DE60110069T2 (de) 2005-09-22
HK1052012A1 (en) 2003-08-29
CA2410220C (en) 2009-04-28
DK1294739T3 (da) 2005-08-01
EP1294739A1 (en) 2003-03-26
KR20030028752A (ko) 2003-04-10
ES2240454T3 (es) 2005-10-16
CN1433426A (zh) 2003-07-30
AR028080A1 (es) 2003-04-23
IL152957A0 (en) 2003-06-24
AU5838601A (en) 2002-01-08
ZA200209452B (en) 2004-02-20
RU2255090C2 (ru) 2005-06-27
US7868193B2 (en) 2011-01-11
WO2002000682A1 (en) 2002-01-03
DE60110069D1 (de) 2005-05-19
EP1294739B1 (en) 2005-04-13
JP2004501931A (ja) 2004-01-22
US20040102426A1 (en) 2004-05-27
NO20025793D0 (no) 2002-12-02
MXPA02012117A (es) 2003-06-06
CA2410220A1 (en) 2002-01-03
SK17072002A3 (sk) 2003-06-03
NO324247B1 (no) 2007-09-17
AU2001258386B2 (en) 2005-08-18
CN1235908C (zh) 2006-01-11
PL203732B1 (pl) 2009-11-30

Similar Documents

Publication Publication Date Title
PT1178045E (pt) Derivados de azaindole-etilamina como agentes de ligacao de receptores de acetilcolina nicotinicos
MX9304541A (es) Esteriodes de 17-espirometileno.
DK1446128T3 (da) Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling
ES2155566T3 (es) Uso de derivados de rifamicina para el tratamiento de enfermedades infecciosas por clamidia.
DE69523622T2 (de) Diastereomerenreine 3-oxo und 3-thioxo-4-aza-androstanderivate und ihre verwendung als antiandrogene
AR005672A1 (es) Derivados de la distamicina, proceso para prepararlos, y su utilizacion como agentes antitumorales y antivirales.
GB2380939B (en) Treatment or prevention of auto-immune diseases
HK1052012A1 (en) 16, 17-Carbocyclic condensed steroid compounds having selective estrogenic activity.
BR0013769A (pt) Esteróides estrogênicos não aromáticos, composição farmacêutica, e, uso de um composto esteróide
HU9202100D0 (en) New 16-methyl-pregna-1,4-diene-3,20-dione derivatives
YU22903A (sh) 17alfa-fluoroalkil steroidi, postupak njihove proizvodnje i farmaceutski sastavi koji sadrže ova jedinjenja
DK0559706T3 (da) 2 beta,19-methylenamino-broforbundne steroider som aromataseinhibitorer.
DK1196428T3 (da) 11-beta-aryl-17,17-spirothiolan-substituerede steroider
NZ508228A (en) 2-aminopyrroline compounds characterised by presence of cyclopropyl group (e.g. N-(2-cyclopropylphenyl)-3,4-dihydro-2H-pyrrol-5-amine, N-(dicyclopropylmethyl)-3,4-dihydro-2H-pyrrol-5-amine or N-(2-cyclopropylphenyl)-2-methyl-3,4-dihydro-2H-pyrrol-5-amine for treating cardiovascular related diseases
ECSP014057A (es) Compuestos esteroides para la modificacion selectiva de la actividad de los receptores de estrogenos
RU2002135594A (ru) 16, 17-карбоциклические конденсированные стероидные соединения, обладающие селективной эстрогенной активностью
MX9801428A (es) Compuestos esteroidales que tiene actividad anticonceptiva y anti-osteoporosis.
NZ333837A (en) estrene steroids for inducing hypothalamic effects

Legal Events

Date Code Title Description
RECP Rectifications of patent specification
LAPS Decisions on the lapse of the protection rights

Effective date: 20110501